TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7970010

Group type: EXPERIMENTAL
Intervention: Tizanidine (maximum dosage of 36 mg/d)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 3653179

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mitozantrone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patient self-assessment and physician assigned toxicity scores
Number of subjects: 22
Study: 30009640

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% (four times daily for 28 days)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% (twice daily for 14 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Steroid-antibiotic combination (Control Group 3)
Number of subjects: 130
Study: 28440351

Group type: EXPERIMENTAL
Intervention: HyperSPACE (Hyper SPectral Analysis for Characterization in Echography) method applied before and after laser treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional ultrasonography and elastography
Number of subjects: 30
Study: 26234471

Group type: EXPERIMENTAL
Intervention: Rosehip powder (3 capsules/day for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (3 identically appearing capsules/day for 12 weeks)
Number of subjects: 100
Study: 23940806

Group type: EXPERIMENTAL
Intervention: Clinical assessment variables at 4 weeks post injury
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Greater age, greater injury grade, and weight‐bearing status at baseline
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Greater age, weight‐bearing status at baseline, and non‐inversion injury mechanisms
Number of subjects: 85
Study: 21605716

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Alfacalcidol (ALF)
Number of subjects: 193
Study: 18304123

Group type: EXPERIMENTAL
Intervention: Beating heart valve replacement with normothermic bypass without cross-clamping the aorta
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Beating heart valve replacement with cross-clamping the aorta and retrograde coronary sinus perfusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional surgery with hypothermic bypass and cardioplegic arrest
Number of subjects: 50
Study: 16542130

Group type: EXPERIMENTAL
Intervention: CBSM+MAT (n = 76)
Number of subjects: 130

Group type: COMPARATOR
Intervention: MAT-only condition (n = 54)
Number of subjects: 130
Study: 12687385

Group type: EXPERIMENTAL
Intervention: Once-daily beclomethasone dipropionate (BDP), 400 micro g/day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Twice-daily beclomethasone dipropionate (BDP), 400 micro g/day
Number of subjects: 112
Study: 11124009

Group type: EXPERIMENTAL
Intervention: Nurse-based pain service with an acute pain nurse, educational programme, and regular pain intensity measurements
Number of subjects: 400

Group type: COMPARATOR
Intervention: Before the introduction of the nurse-based pain service
Number of subjects: 400
Study: 8639070

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1513607

Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day in two divided doses for 10 days
Number of subjects: 290

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 40 mg/kg/day in three divided doses for 10 days
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day in two divided doses for 7 days
Number of subjects: 290

Group type: COMPARATOR
Intervention: Amoxicillin 40 mg/kg/day in three divided doses for 7 days
Number of subjects: 290
Study: 3884968

Group type: EXPERIMENTAL
Intervention: Diet with supplemental essential amino acids (80% nitrogen as essential amino acids)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diet with nonessential amino acids (80% nitrogen as nonessential amino acids)
Number of subjects: 6
Study: 31268891

Group type: EXPERIMENTAL
Intervention: Comorbid insomnia
Number of subjects: 17920
Study: 29199551

Group type: EXPERIMENTAL
Intervention: Agaricus brasiliensis supplementation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 25394638

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 24887336

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (0.5 µg/kg, 1 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (0.5 µg/kg, 20 mL)
Number of subjects: 60
Study: 23164044

Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) patient education program in primary health care, conducted by trained district nurses, 13 sessions of 2 hours each over one year.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standardized home-sent patient information, 11 occasions during the year.
Number of subjects: 165
Study: 19910831

Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 40
Study: 17302653

Group type: EXPERIMENTAL
Intervention: glargine+OAD
Number of subjects: 130

Group type: COMPARATOR
Intervention: 70/30
Number of subjects: 130
Study: 15151839

Group type: EXPERIMENTAL
Intervention: hs‐CRP and TC/HDL‐C ratio
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: hs‐CRP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: TC/HDL‐C
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: hs‐CRP combined with TC/HDL‐C
Number of subjects: 240
Study: 11831545

Group type: EXPERIMENTAL
Intervention: 175 mg rofecoxib
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study: 10192855

Group type: EXPERIMENTAL
Intervention: DDIR pacing
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DDDR pacing with mode switch
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study: 7749286

Group type: EXPERIMENTAL
Intervention: Stapled Roux-en-Y anastomosis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hand-sewn Roux-en-Y anastomosis
Number of subjects: 22
Study: 2261900

Group type: EXPERIMENTAL
Intervention: Individual dietary counselling aimed at reducing dietary fat intake to 20‐25% of energy while increasing intake of carbohydrates
Number of subjects: 240

Group type: COMPARATOR
Intervention: No dietary advice
Number of subjects: 240
Study: 7446596

Group type: EXPERIMENTAL
Intervention: Respond as quickly and accurately as possible
Number of subjects: 16

Group type: COMPARATOR
Intervention: Respond accurately with praise for slower RT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stimulus-exposure durations varied randomly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stimulus-exposure durations arranged in regular blocks from long to short
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Retarded subjects
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonretarded subjects
Number of subjects: 16
Study: 6421778

Group type: EXPERIMENTAL
Intervention: Nutritional support (1800 kcal, 70 g protein) by naso-jejunal tube for 7-10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unmodified hospital diet
Number of subjects: 8
Study: 31930893

Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with vibration training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple vibration training
Number of subjects: 60
Study: 29437590

Group type: EXPERIMENTAL
Intervention: Total metabolic tumor volume (TMTV) measured on baseline PET
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Interim PET (iPET2) findings
Number of subjects: 258

Group type: COMPARATOR
Intervention: Combined modality treatment (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 258
Study: 27722221

Group type: EXPERIMENTAL
Intervention: Immediate non-occlusally loaded implants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 24773371

Group type: EXPERIMENTAL
Intervention: Absorbable mesh fixed with absorbable tacks and/or fibrin glue
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tacks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tacks plus fibrin glue
Number of subjects: 43
Study: 23169801

Group type: EXPERIMENTAL
Intervention: Intensive structured care (computer assisted clinical profiling and risk target setting, intensified follow-up, stepwise drug titration)
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Intensive structured care
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1562
Study: 19709689

Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d, n = 19)
Number of subjects: 60

Group type: COMPARATOR
Intervention: rosiglitazone (4 mg/d, n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo (medical nutrition therapy, n = 21)
Number of subjects: 60
Study: 19192864

Group type: EXPERIMENTAL
Intervention: Deposit contract ($50.00)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No-deposit group
Number of subjects: 8
Study: 15004572

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3% (Ciloxan)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin and dexamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dexamethasone phosphate 0.1% (Maxidex)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Artificial tear solution (Tears Naturale)
Number of subjects: 100
Study: 11303266

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cefixime, 400 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (MICs > or = 4.0 microg/mL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (MICs < 4.0 microg/mL)
Number of subjects: 105
Study: 9164216

Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy (750 mg/m2 daily fluorouracil on days 1 to 5 and 29 to 33, and 15 mg/m2 mitomycin on day 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Number of subjects: 110
Study: 7700062

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 4000000

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 4000000
Study: 2438902

Group type: EXPERIMENTAL
Intervention: Thermochemotherapy (hyperthermia combined with chemotherapy)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 69
Study: 30094663

Group type: EXPERIMENTAL
Intervention: Lifestyle-based program delivered by lay volunteers (social interaction, nutritional and physical exercise interventions)
Number of subjects: 0
Study: 27003163

Group type: EXPERIMENTAL
Intervention: Active (soft elastomer roller)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (hard polystyrene roller)
Number of subjects: 24
Study: 24169364

Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS (atDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS (stDCS)
Number of subjects: 0
Study: 22771293

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Number of subjects: 198

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 198
Study: 20397456

Group type: EXPERIMENTAL
Intervention: blood‐letting cupping plus herbal medicine
Number of subjects: 34
Study: 17955168

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (traditional Chinese medicine)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Sham acupuncture (superficial needling at nonacupuncture points)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 409

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 409
Study: 16274386

Group type: EXPERIMENTAL
Intervention: High mortality risk group
Number of subjects: 2255

Group type: COMPARATOR
Intervention: Low mortality risk group
Number of subjects: 2255
Study: 12418393

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study: 9845397

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8010718

Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (FA) plus fluorouracil (FU)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TS) added to FA-FU
Number of subjects: 211
Study: 2658897

Group type: EXPERIMENTAL
Intervention: Mezlocillin therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ampicillin-gentamicin therapy
Number of subjects: 46
Study: 4921284

Group type: EXPERIMENTAL
Intervention: Clonidine-chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa-chlorthalidone
Number of subjects: 0
Study: 31948512

Group type: EXPERIMENTAL
Intervention: Strengths for the Journey (SFJ) intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-listed group
Number of subjects: 72
Study: 30154236

Group type: EXPERIMENTAL
Intervention: Automated FiO2 adjustment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual FiO2 adjustment
Number of subjects: 12
Study: 27899357

Group type: EXPERIMENTAL
Intervention: Inolimomab
Number of subjects: 100

Group type: COMPARATOR
Intervention: ATG (usual care)
Number of subjects: 100
Study: 26732807

Group type: EXPERIMENTAL
Intervention: Syndrome Evaluation System (SES)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Blood Culture (BACTEC)
Number of subjects: 385
Study: 25099872

Group type: EXPERIMENTAL
Intervention: web- and text messaging-based intervention providing online feedback and tailored text messages, up to two weekly messages for 3 months
Number of subjects: 934

Group type: COMPARATOR
Intervention: assessment only (control group)
Number of subjects: 934
Study: 22464991

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study: 19545453

Group type: EXPERIMENTAL
Intervention: Structured warm-up program at two training sessions per week throughout the 2009 competitive season (April to October)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Training and playing as usual (Control group)
Number of subjects: 516
Study: 17309596

Group type: COMPARATOR
Intervention: SRP alone (N=23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP + 500 mg azithromycin per day for 3 days (N=25)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP + 250 mg metronidazole tid for 14 days (N=24)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP + 20 mg doxycycline bid for 3 months (N=20)
Number of subjects: 92
Study: 15125464

Group type: EXPERIMENTAL
Intervention: OAM (omeprazole, amoxycillin and metronidazole) for H. pylori-positive patients (Hp+/erad)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-positive patients (Hp+/ome)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/ome)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for H. pylori-negative patients (Hp-/erad)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: H. pylori-negative patients (Hp-/ome)
Number of subjects: 1552
Study: 11591944

Group type: EXPERIMENTAL
Intervention: Humidified carbon dioxide (CO2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard dry carbon dioxide (CO2)
Number of subjects: 40
Study: 10457551

Group type: EXPERIMENTAL
Intervention: Single 800 mg injection of Pefloxacin (PF)
Number of subjects: 616

Group type: COMPARATOR
Intervention: 2 days of cefazolin (1 gr.Q.6 H) followed by 3 days of oxacillin (1 gr.Q.8 H) (CZ-OX)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Pefloxacin (PF)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Cefazolin-oxacillin (CZ-OX)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 616
Study: 8574175

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (L-leucine 12 g, L-isoleucine 6 g, L-valine 6 g daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Number of subjects: 24
Study: 2222100

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus rifampin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sulfamethoxazole and trimethoprim plus rifampin
Number of subjects: 21
Study: 895002

Group type: EXPERIMENTAL
Intervention: alpha-acetyldigoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: beta-acetyldigoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: new formulation isolating beta-acetyldigoxin from potassium-magnesium-aspartate
Number of subjects: 0
Study: 31882586

Group type: EXPERIMENTAL
Intervention: Primary tumor surgery (S)
Number of subjects: 1415

Group type: COMPARATOR
Intervention: No surgery (non-S)
Number of subjects: 1415
Study: 28236780

Group type: EXPERIMENTAL
Intervention: Family-centred, feedback-informed intervention
Number of subjects: 26
Study: 25788569

Group type: EXPERIMENTAL
Intervention: Low-dose human menopausal gonadotrophin (hMG) 37.5-75 IU per day
Number of subjects: 330

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg/day from Day 3-7
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Low-dose human menopausal gonadotrophin (hMG)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 330
Study: 24373363

Group type: EXPERIMENTAL
Intervention: Sleep restriction (6 hours nightly)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Exercise cessation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both sleep restriction and exercise cessation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 87
Study: 21389925

Group type: EXPERIMENTAL
Intervention: Oxidized Regenerated Cellulose (ORC) applied to surgical wounds
Number of subjects: 98

Group type: COMPARATOR
Intervention: Gauze soaked in iodine
Number of subjects: 98
Study: 19153941

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 to 8 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 16953261

Group type: EXPERIMENTAL
Intervention: Cetilistat 60 mg t.i.d.
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d.
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Cetilistat 240 mg t.i.d.
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Cetilistat (all doses)
Number of subjects: 371
Study: 15372383

Group type: EXPERIMENTAL
Intervention: Bier block with methylprednisolone (40 mg) and lidocaine (10 mL of 2% solution)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (100 mL of saline)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bier block with methylprednisolone and lidocaine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11465642

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg patches)
Number of subjects: 0
Study: 9604636

Group type: EXPERIMENTAL
Intervention: Acupuncture (15 treatments over 3 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Individualised physiotherapy
Number of subjects: 22
Study: 1620298

Group type: EXPERIMENTAL
Intervention: FUT-175 (Group A: 20 mg every 12 hours for 4 days; Group B: 20 mg every 6 hours for 4 days; Group C: 40 mg every 6 hours for 4 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FUT-175 (higher doses: Groups B and C)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FUT-175 (all groups)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no FUT-175)
Number of subjects: 23
Study: 6366808

Group type: EXPERIMENTAL
Intervention: 10 mg serrapeptase 3 times on the day before operation, once on the night of the operation and 3 times daily for 5 days after operation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 31437295

Group type: EXPERIMENTAL
Intervention: Repetitive text messaging with key details from the class
Number of subjects: 0

Group type: COMPARATOR
Intervention: No text messages (Control group)
Number of subjects: 0
Study: 30064993

Group type: EXPERIMENTAL
Intervention: Primary Care (PC)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Sleep Unit (SU)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI)
Number of subjects: 302
Study: 27287832

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 317

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tocilizumab plus methotrexate vs Methotrexate
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tocilizumab vs Methotrexate
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate vs Tocilizumab
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 317
Study: 24331381

Group type: EXPERIMENTAL
Intervention: Transcutaneous yellow fever virus (YFV) vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous yellow fever virus (YFV) vaccination
Number of subjects: 0
Study: 22529163

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl therapy
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study: 19243009

Group type: EXPERIMENTAL
Intervention: High-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose radiosurgery (20 or 24Gy targeting the amygdala, hippocampus, and parahippocampal gyrus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both high-dose and low-dose radiosurgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-dose and low-dose radiosurgery
Number of subjects: 30